Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 5, 2016, Pages 966-974

  Ishii, Makoto ^a   Iadecola, Costantino ^a  

^a FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

Adiponectin; Adiposity; Alzheimer's; Dementia; Leptin; Vascular

Indexed keywords

ADIPONECTIN; LEPTIN;

ADIPOCYTE; ADIPOSE TISSUE; AGE RELATED DEMENTIA; ALZHEIMER DISEASE; BODY WEIGHT; CEREBROVASCULAR DISEASE; DEMENTIA; HUMAN; MULTIINFARCT DEMENTIA; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 84960869778     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.10.029     Document Type: Review

References (125)

1. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, 88:640-651.
2. Musiek E.S., Holtzman D.M. Three dimensions of the amyloid hypothesis: time, space and "wingmen,". Nat. Neurosci. 2015, 18:800-806.
3. Iadecola C. The pathobiology of vascular dementia. Neuron 2013, 80:844-866.
4. Attems J., Jellinger K.A. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med. 2014, 12:206.
5. Chui H.C., Ramirez-Gomez L. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res. Ther. 2015, 7:21.
6. Gorelick P.B., Scuteri A., Black S.E., DeCarli C., Greenberg S.M., Iadecola C., Launer L.J., Laurent S., Lopez O.L., Nyenhuis D., Petersen R.C., Schneider J.A., Tzourio C., Arnett D.K., Bennett D.A., Chui H.C., Higashida R.T., Lindquist R., Nilsson P.M., Roman G.C., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:2672-2713.
7. Emmerzaal T.L., Kiliaan A.J., Gustafson D.R. 2003-2013: a decade of body mass index, Alzheimer's disease, and dementia. J. Alzheimers Dis. 2015, 43:739-755.
8. Iadecola C. Hypertension and dementia. Hypertension 2014, 64:3-5.
9. Kim B., Feldman E.L. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp. Mol. Med. 2015, 47.
10. Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096. Prospective Studies Collaboration.
11. Qatanani M., Lazar M.A. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007, 21:1443-1455.
12. Hall J.E., do Carmo J.M., da Silva A.A., Wang Z., Hall M.E. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ. Res. 2015, 116:991-1006.
13. Ishii M., Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target. Cell Metab. 2015, http://dx.doi.org/10.1016/j.cmet.2015.08.016.
14. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 2014, 6:37.
15. Zea-Sevilla M.A., Fernández-Blázquez M.A., Calero M., Bermejo-Velasco P., Rábano A. Combined Alzheimer's disease and cerebrovascular staging explains advanced dementia cognition. Alzheimers Dement. 2015.
16. Gaddey H.L., Holder K. Unintentional weight loss in older adults. Am. Fam. Physician 2014, 89:718-722.
17. Schaap L.A., Koster A., Visser M. Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol. Rev. 2013, 35:51-65.
18. Mott J.W., Wang J., Thornton J.C., Allison D.B., Heymsfield S.B., Richard N Pierson J. Relation between body fat and age in 4 ethnic groups. Am. J. Clin. Nutr. 1999, 69:1007-1013.
19. Inzitari M., Doets E., Bartali B., Benetou V., Di Bari M., Visser M., Volpato S., Gambassi G., Topinkova E., De Groot L., Salva A., International Association of Gerontology and Geriatrics (IAGG) task force for nutrition in the elderly Nutrition in the age-related disablement process. J. Nutr. Health Aging 2011, 599-604.
20. Perry H.M., Morley J.E., Horowitz M., Kaiser F.E., Miller D.K., Wittert G. Body composition and age in African-American and Caucasian women: relationship to plasma leptin levels. Metab. Clin. Exp. 1997, 46:1399-1405.
21. Ding J., Kritchevsky S.B., Newman A.B., Taaffe D.R., Nicklas B.J., Visser M., Lee J.S., Nevitt M., Tylavsky F.A., Rubin S.M., Pahor M., Harris T.B. Health ABC study, effects of birth cohort and age on body composition in a sample of community-based elderly. Am. J. Clin. Nutr. 2007, 85:405-410.
22. Balaskó M., Soós S., Székely M., Pétervári E. Leptin and aging: review and questions with particular emphasis on its role in the central regulation of energy balance. J. Chem. Neuroanat. 2014, 61-62:248-255.
23. Paschos G.K. Circadian clocks, feeding time, and metabolic homeostasis. Front. Pharmacol. 2015, 6.
24. Coomans C.P., Lucassen E.A., Kooijman S., Fifel K., Deboer T., Rensen P.C.N., Michel S., Meijer J.H. Plasticity of circadian clocks and consequences for metabolism. Diabetes Obes. Metab. 2015, 17:65-75.
25. Xu W.L., Atti A.R., Gatz M., Pedersen N.L., Johansson B., Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011, 76:1568-1574.
26. Whitmer R.A., Gustafson D.R., Barrett-Connor E., Haan M.N., Gunderson E.P., Yaffe K. Central obesity and increased risk of dementia more than three decades later. Neurology 2008, 71:1057-1064.
27. Hassing L.B., Dahl A.K., Thorvaldsson V., Berg S., Gatz M., Pedersen N.L., Johansson B. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J. Obes. 2009, 33:893-898.
28. Morris M.C., Tangney C.C. Dietary fat composition and dementia risk. Neurobiol. Aging 2014, 35(Suppl 2):S59-S64.
29. Refolo L.M., Malester B., Lafrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K., Pappolla M.A. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
30. Julien C., Tremblay C., Phivilay A., Berthiaume L., Emond V., Julien P., Calon F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging 2010, 31:1516-1531.
31. Whitmer R.A., Gunderson E.P., Barrett-Connor E., Quesenberry C.P., Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005, 330. (1360-0).
32. Kivipelto M., Ngandu T., Fratiglioni L., Viitanen M., Kåreholt I., Winblad B., Helkala E.-L., Tuomilehto J., Soininen H., Nissinen A. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 2005, 62:1556-1560.
33. Chiang C.-J., Yip P.-K., Wu S.-C., Lu C.-S., Liou C.-W., Liu H.-C., Liu C.-K., Chu C.-H., Hwang C.-S., Sung S.-F., Hsu Y.-D., Chen C.-C., Liu S.-I., Yan S.-H., Fong C.-S., Chang S.-F., You S.-L., Chen C.-J. Midlife risk factors for subtypes of dementia: a nested case-control study in Taiwan. Am. J. Geriatr. Psychiatr. 2007, 15:762-771.
34. Qizilbash N., Gregson J., Johnson M.E., Pearce N., Douglas I., Wing K., Evans S.J.W., Pocock S.J. BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes Endocrinol 2015, 3:431-436.
35. Kamogawa K., Kohara K., Tabara Y., Uetani E., Nagai T., Yamamoto M., Igase M., Miki T. Abdominal fat, adipose-derived hormones and mild cognitive impairment: the J-SHIPP study. Dement. Geriatr. Cogn. Disord. 2010, 30:432-439.
36. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease. Neurology 1984, 34:939-944.
37. White H., Pieper C., Schmader K., Fillenbaum G. Weight change in Alzheimer's disease. J. Am. Geriatr. Soc. 1996, 44:265-272.
38. White H., Pieper C., Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J. Am. Geriatr. Soc. 1998, 46:1223-1227.
39. Power B.D., Alfonso H., Flicker L., Hankey G.J., Yeap B.B., Almeida O.P. Changes in body mass in later life and incident dementia. Int. Psychogeriatr. 2013, 25:467-478.
40. Johnson D.K., Wilkins C.H., Morris J.C. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch. Neurol. 2006, 63:1312-1317.
41. Hughes T.F., Borenstein A.R., Schofield E., Wu Y., Larson E.B. Association between late-life body mass index and dementia: the Kame Project. Neurology 2009, 72:1741-1746.
42. Buchman A.S., Wilson R.S., Bienias J.L., Shah R.C., Evans D.A., Bennett D.A. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65:892-897.
43. Barrett-Connor E., Edelstein S.L., Corey-Bloom J., Wiederholt W.C. Weight loss precedes dementia in community-dwelling older adults. J. Am. Geriatr. Soc. 1996, 44:1147-1152.
44. Stewart R., Masaki K., Xue Q.-L., Peila R., Petrovitch H., White L.R., Launer L.J. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 2005, 62:55-60.
45. Gao S., Nguyen J.T., Hendrie H.C., Unverzagt F.W., Hake A., Smith-Gamble V., Hall K. Accelerated weight loss and incident dementia in an elderly African-American cohort. J. Am. Geriatr. Soc. 2011, 59:18-25.
46. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
47. Buchman A.S., Schneider J.A., Wilson R.S., Bienias J.L., Bennett D.A. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 2006, 67:1949-1954.
48. Vidoni E.D., Townley R.A., Honea R.A., Burns J.M., Alzheimer's Disease Neuroimaging Initiative Alzheimer disease biomarkers are associated with body mass index. Neurology 2011, 77:1913-1920.
49. Ewers M., Schmitz S., Hansson O., Walsh C., Fitzpatrick A., Bennett D., Minthon L., Trojanowski J.Q., Shaw L.M., Faluyi Y.O., Vellas B., Dubois B., Blennow K., Buerger K., Teipel S.J., Weiner M., Hampel H., Alzheimer's Disease Neuroimaging Initiative Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol. Aging 2012, 33:1599-1608.
50. Ishii M., Wang G., Racchumi G., Dyke J.P., Iadecola C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J. Neurosci. 2014, 34:9096-9106.
51. Ishii M., Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target of pathology. Cell Metab. 2015.
52. Friedman J.M., Mantzoros C.S. 20 years of leptin: from the discovery of the leptin gene to leptin in our therapeutic armamentarium. Metab. Clin. Exp. 2015, 64:1-4.
53. Blüher M., Mantzoros C.S. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metab. Clin. Exp. 2015, 64:131-145.
54. Friedman J. 20 years of leptin: leptin at 20: an overview. J. Endocrinol. 2014, 223:T1-T8.
55. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., Fei H., Kim S., Lallone R., Ranganathan S., Kern P.A., Friedman J.M. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med. 1995, 1:1155-1161.
56. Boden G., Chen X., Mozzoli M., Ryan I. Effect of fasting on serum leptin in normal human subjects. J. Clin. Endocrinol. Metab. 1996, 81:3419-3423.
57. Ruhl C.E., Harris T.B., Ding J., Goodpaster B.H., Kanaya A.M., Kritchevsky S.B., Simonsick E.M., Tylavsky F.A., Everhart J.E. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am. J. Clin. Nutr. 2007, 85:1121-1126.
58. Ruhl C.E., Everhart J.E. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am. J. Clin. Nutr. 2001, 74:295-301.
59. Allison M.B., Myers M.G. 20 years of leptin: connecting leptin signaling to biological function. J. Endocrinol. 2014, 223:T25-T35.
60. Coppari R., Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discov. 2012, 11:692-708.
61. Knights A.J., Funnell A.P., Pearson R.C., Crossley M., Bell-Anderson K.S. Adipokines and insulin action: a sensitive issue. Adipocytes 2014, 3:88-96.
62. Simonds S.E., Pryor J.T., Ravussin E., Greenway F.L., Dileone R., Allen A.M., Bassi J., Elmquist J.K., Keogh J.M., Henning E., Myers M.G., Licinio J., Brown R.D., Enriori P.J., O'Rahilly S., Sternson S.M., Grove K.L., Spanswick D.C., Farooqi I.S., Cowley M.A. Leptin mediates the increase in blood pressure associated with obesity. Cell 2014, 159:1404-1416.
63. Brown R.J., Meehan C.A., Gorden P. Leptin does not mediate hypertension associated with human obesity. Cell 2015, 162:465-466.
64. Dalamaga M., Chou S.H., Shields K., Papageorgiou P., Polyzos S.A., Mantzoros C.S. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013, 18:29-42.
65. Farooqi I.S., Jebb S.A., Langmack G., Lawrence E., Cheetham C.H., Prentice A.M., Hughes I.A., McCamish M.A., O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341:879-884.
66. Myers M.G., Heymsfield S.B., Haft C., Kahn B.B., Laughlin M., Leibel R.L., Tschöp M.H., Yanovski J.A. Challenges and opportunities of defining clinical leptin resistance. Cell Metab. 2012, 15:150-156.
67. Heymsfield S.B., Greenberg A.S., Fujioka K., Dixon R.M., Kushner R., Hunt T., Lubina J.A., Patane J., Self B., Hunt P., McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999, 282:1568-1575.
68. Paz-Filho G., Mastronardi C.A., Licinio J. Leptin treatment: facts and expectations. Metab. Clin. Exp. 2015, 64:146-156.
69. Zhang F., Wang S., Signore A.P., Chen J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke 2007, 38:2329-2336.
70. Zhang F., Chen J. Leptin protects hippocampal CA1 neurons against ischemic injury. J. Neurochem. 2008, 107:578-587.
71. Busch H.-J., Schirmer S.H., Jost M., van Stijn S., Peters S.L.M., Piek J.J., Bode C., Buschmann I.R., Mies G. Leptin augments cerebral hemodynamic reserve after three-vessel occlusion: distinct effects on cerebrovascular tone and proliferation in a nonlethal model of hypoperfused rat brain. J. Cereb. Blood Flow Metab. 2011, 31:1085-1092.
72. Terao S., Yilmaz G., Stokes K.Y., Ishikawa M., Kawase T., Granger D.N. Inflammatory and injury responses to ischemic stroke in obese mice. Stroke 2008, 39:943-950.
73. Guo Z., Jiang H., Xu X., Duan W., Mattson M.P. Leptin-mediated cell survival signaling in hippocampal neurons mediated by JAK STAT3 and mitochondrial stabilization. J. Biol. Chem. 2008, 283:1754-1763.
74. Söderberg S., Stegmayr B., Ahlbeck-Glader C., Slunga-Birgander L., Ahrén B., Olsson T. High leptin levels are associated with stroke. Cerebrovasc. Dis. 2003, 15:63-69.
75. Jaleel A., Aqil S., Jaleel S., Jaleel F. Adipocytokines in subjects with and without ischemic cerebrovascular disease. Acta Neurol. Belg. 2010, 110:234-238.
76. Jalil A., Amir S., Majeed R., Jalil F. Circulating leptin levels in elderly subjects with and without cerebrovascular disease. J. Coll. Physicians Surg. Pak. 2010, 20:350-351.
77. Davis C., Mudd J., Hawkins M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. Neurobiol. Dis. 2014, 72 Pt A:61-71.
78. Fewlass D.C., Noboa K., Pi-Sunyer F.X., Johnston J.M., Yan S.D., Tezapsidis N. Obesity-related leptin regulates Alzheimer's abeta. FASEB J. 2004, 18:1870-1878.
79. Marwarha G., Raza S., Meiers C., Ghribi O. Leptin attenuates BACE1 expression and amyloid-β genesis via the activation of SIRT1 signaling pathway. Biochim. Biophys. Acta 2014, 1842:1587-1595.
80. Yamamoto N., Tanida M., Kasahara R., Sobue K., Suzuki K. Leptin inhibits amyloid β-protein fibrillogenesis by decreasing GM1 gangliosides on the neuronal cell surface through PI3K/Akt/mTOR pathway. J. Neurochem. 2014, 131:323-332.
81. Greco S.J., Hamzelou A., Johnston J.M., Smith M.A., Ashford J.W., Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons. Biochem. Biophys. Res. Commun. 2011, 414:170-174.
82. Marwarha G., Dasari B., Prasanthi J.R.P., Schommer J., Ghribi O. Leptin reduces the accumulation of abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 2010, 19:1007-1019.
83. Greco S.J., Bryan K.J., Sarkar S., Zhu X., Smith M.A., Ashford J.W., Johnston J.M., Tezapsidis N., Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 2010, 19:1155-1167.
84. Pérez-González R., Alvira-Botero M.X., Robayo O., Antequera D., Garzón M., Martín-Moreno A.M., Brera B., de Ceballos M.L., Carro E. Leptin gene therapy attenuates neuronal damages evoked by amyloid-β and rescues memory deficits in app/ps1 mice. Gene Ther. 2014.
85. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Morishita R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U.S.A 2010, 107:7036-7041.
86. Oania R., McEvoy L.K. Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. Age Ageing 2015, 44:53-58.
87. Teunissen C.E., van der Flier W.M., Scheltens P., Duits A., Wijnstok N., Nijpels G., Dekker J.M., Blankenstein R.M.A., Heijboer A.C. Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. J. Alzheimers Dis. 2015, 44:809-813.
88. Holden K.F., Lindquist K., Tylavsky F.A., Rosano C., Harris T.B., Yaffe K., Health ABC Study Serum leptin level and cognition in the elderly: findings from the Health ABC Study. Neurobiol. Aging 2009, 30:1483-1489.
89. Lieb W., Beiser A.S., Vasan R.S., Tan Z.S., Au R., Harris T.B., Roubenoff R., Auerbach S., DeCarli C., Wolf P.A., Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA 2009, 302:2565-2572.
90. Bigalke B., Schreitmüller B., Sopova K., Paul A., Stransky E., Gawaz M., Stellos K., Laske C. Adipocytokines and CD34 progenitor cells in Alzheimer's disease. PLoS One 2011, 6.
91. Khemka V.K., Bagchi D., Bandyopadhyay K., Bir A., Chattopadhyay M., Biswas A., Basu D., Chakrabarti S. Altered serum levels of adipokines and insulin in probable Alzheimer's disease. J. Alzheimers Dis. 2014, 41:525-533.
92. Baranowska-Bik A., Bik W., Styczynska M., Chodakowska-Zebrowska M., Barcikowska M., Wolinska-Witort E., Kalisz M., Martynska L., Baranowska B. Plasma leptin levels and free leptin index in women with Alzheimer's disease. Neuropeptides 2015, 52:73-78.
93. Reed D.R., Bachmanov A.A., Tordoff M.G. Forty mouse strain survey of body composition. Physiol. Behav. 2007, 91:593-600.
94. Vloeberghs E., Van Dam D., Franck F., Serroyen J., Geert M., Staufenbiel M., De Deyn P.P. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav. Neurosci. 2008, 122:491-497.
95. Wirths O., Breyhan H., Schäfer S., Roth C., Bayer T.A. Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol. Aging 2008, 29:891-901.
96. Pugh P.L., Richardson J.C., Bate S.T., Upton N., Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav. Brain Res. 2007, 178:18-28.
97. Li G., Jack C.R., Yang X.-F., Yang E.S. Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors 2008, 32:169-178.
98. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270:26746-26749.
99. Turer A.T., Scherer P.E. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012, 55:2319-2326.
100. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
101. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
102. Qi Y., Takahashi N., Hileman S.M., Patel H.R., Berg A.H., Pajvani U.B., Scherer P.E., Ahima R.S. Adiponectin acts in the brain to decrease body weight. Nat. Med. 2004, 10:524-529.
103. Okada-Iwabu M., Yamauchi T., Iwabu M., Honma T., Hamagami K.-I., Matsuda K., Yamaguchi M., Tanabe H., Kimura-Someya T., Shirouzu M., Ogata H., Tokuyama K., Ueki K., Nagano T., Tanaka A., Yokoyama S., Kadowaki T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 2013, 503:493-499.
104. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 2002, 8:731-737.
105. Yang Y., Hu W., Jiang S., Wang B., Li Y., Fan C., Di S., Ma Z., Lau W.B., Qu Y. The emerging role of adiponectin in cerebrovascular and neurodegenerative diseases. Biochim. Biophys. Acta 2015, 1852:1887-1894.
106. Chen M.-P., Tsai J.C.-R., Chung F.-M., Yang S.-S., Hsing L.-L., Shin S.-J., Lee Y.-J. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25:821-826.
107. Sasaki M., Kawano T., Saito T., Yuzawa M., Saito T., Ikoma A., Tamemoto H., Kawakami M., Ishikawa S.-E. Hypoadiponectinemia in patients with cerebral infarction: comparison with other atherosclerotic disorders. Am. J. Med. Sci. 2007, 333:140-144.
108. Kuwashiro T., Ago T., Kamouchi M., Matsuo R., Hata J., Kuroda J., Fukuda K., Sugimori H., Fukuhara M., Awano H., Isomura T., Suzuki K., Yasaka M., Okada Y., Kiyohara Y., Kitazono T. Significance of plasma adiponectin for diagnosis, neurological severity and functional outcome in ischemic stroke - Research for Biomarkers in Ischemic Stroke (REBIOS). Metab. Clin. Exp. 2014, 63:1093-1103.
109. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., Gratsias Y.E., Pefanis A.V., Mountokalakis T.D. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 2005, 36:1915-1919.
110. Shen L., Miao J., Yuan F., Zhao Y., Tang Y., Wang Y., Zhao Y., Yang G.-Y. Overexpression of adiponectin promotes focal angiogenesis in the mouse brain following middle cerebral artery occlusion. Gene Ther. 2013, 20:93-101.
111. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., Shin H.K., Moskowitz M.A., Ouchi N. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
112. Chen B., Liao W.-Q., Xu N., Xu H., Wen J.-Y., Yu C.-A., Liu X.-Y., Li C.-L., Zhao S.-M., Campbell W. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res. 2009, 1273:129-137.
113. Chan K.-H., Lam K.S.-L., Cheng O.-Y., Kwan J.S.-C., Ho P.W.-L., Cheng K.K.-Y., Chung S.K., Ho J.W.-M., Guo V.Y., Xu A. Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity. PLoS One 2012, 7.
114. Une K., Takei Y.A., Tomita N., Asamura T., Ohrui T., Furukawa K., Arai H. Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer's disease. Eur. J. Neurol. 2011, 18:1006-1009.
115. van Himbergen T.M., Beiser A.S., Ai M., Seshadri S., Otokozawa S., Au R., Thongtang N., Wolf P.A., Schaefer E.J. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 2012, 69:594-600.
116. Lin H.V., Kim J.-Y., Pocai A., Rossetti L., Shapiro L., Scherer P.E., Accili D. Adiponectin resistance exacerbates insulin resistance in insulin receptor transgenic/knockout mice. Diabetes 2007, 56:1969-1976.
117. Li R., Lau W.B., Ma X.L. Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacol. Sin. 2010, 31:1258-1266.
118. Warren M.W., Hynan L.S., Weiner M.F. Lipids and adipokines as risk factors for Alzheimer's disease. J. Alzheimers Dis. 2012, 29:151-157.
119. Teixeira A.L., Diniz B.S., Campos A.C., Miranda A.S., Rocha N.P., Talib L.L., Gattaz W.F., Forlenza O.V. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease. Neruomol. Med. 2013, 15:115-121.
120. Kiliaan A.J., Arnoldussen I.A.C., Gustafson D.R. Adipokines: a link between obesity and dementia?. Lancet Neurol. 2014, 13:913-923.
121. Aguilar-Valles A., Inoue W., Rummel C., Luheshi G.N. Obesity, adipokines and neuroinflammation. Neuropharmacology 2015, 96:124-134.
122. Bruce-Keller A.J., Salbaum J.M., Luo M., Blanchard E., Taylor C.M., Welsh D.A., Berthoud H.-R. Obese-type gut microbiota induce neurobehavioral changes in the absence of obesity. Biol. Psychiatry 2015, 77:607-615.
123. Fitzpatrick A.L., Kuller L.H., Lopez O.L., Diehr P., O'Meara E.S., Longstreth W.T., Luchsinger J.A. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66:336-342.
124. Ravona-Springer R., Schnaider-Beeri M., Goldbourt U. Body weight variability in midlife and risk for dementia in old age. Neurology 2013, 80:1677-1683.
125. Tolppanen A.-M., Ngandu T., Kåreholt I., Laatikainen T., Rusanen M., Soininen H., Kivipelto M. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J. Alzheimers Dis. 2014, 38:201-209.